Nautilus Biotechnology (NAUT) Set to Announce Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUTGet Rating) will be releasing its earnings data before the market opens on Tuesday, May 3rd. Analysts expect Nautilus Biotechnology to post earnings of ($0.15) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Nautilus Biotechnology (NASDAQ:NAUTGet Rating) last released its quarterly earnings results on Thursday, February 24th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:NAUT opened at $4.23 on Tuesday. The stock’s 50 day moving average price is $4.02 and its 200 day moving average price is $4.64. Nautilus Biotechnology has a 52-week low of $3.36 and a 52-week high of $12.38.

NAUT has been the topic of a number of research reports. Morgan Stanley initiated coverage on Nautilus Biotechnology in a research note on Thursday, January 6th. They set an “equal weight” rating and a $8.00 price target on the stock. Zacks Investment Research downgraded Nautilus Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, The Goldman Sachs Group dropped their price target on Nautilus Biotechnology from $9.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.67.

In related news, CEO Sujal M. Patel bought 50,000 shares of the stock in a transaction on Thursday, March 3rd. The shares were bought at an average cost of $3.60 per share, for a total transaction of $180,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of Nautilus Biotechnology by 1.9% in the 4th quarter. BlackRock Inc. now owns 1,251,848 shares of the company’s stock valued at $6,485,000 after buying an additional 23,560 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Nautilus Biotechnology by 28.3% in the 4th quarter. Geode Capital Management LLC now owns 495,198 shares of the company’s stock valued at $2,565,000 after buying an additional 109,327 shares during the period. Millennium Management LLC lifted its holdings in shares of Nautilus Biotechnology by 655.0% in the 3rd quarter. Millennium Management LLC now owns 287,649 shares of the company’s stock valued at $1,766,000 after buying an additional 249,548 shares during the period. State Street Corp lifted its holdings in shares of Nautilus Biotechnology by 12.4% in the 4th quarter. State Street Corp now owns 177,200 shares of the company’s stock valued at $918,000 after buying an additional 19,500 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Nautilus Biotechnology by 453.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 57,676 shares of the company’s stock valued at $299,000 after buying an additional 47,253 shares during the period. 33.40% of the stock is owned by institutional investors and hedge funds.

About Nautilus Biotechnology (Get Rating)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

Recommended Stories

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.